Strides Acrolab to market generic cancer injection
Bangalore, July 20 : Indian pharmaceutical company Strides Arcolab on Friday announced it had received approval from the U S Food and Drug Administration (USFDA) for the its generic anti-cancer injection Fluorouracil Injection.
The company's wholly-owned subsidiary Onco Therapies Ltd received two approvals from the USFDA for the injection in the strengths of 50 mg / ml, packaged in 10 ml and 20 ml single-dose vials and 2.5 g/ 50 ml and 5 g / 100 ml pharmacy bulk packages, Strides Arcolab said in a statement
"It (Fluorouracil) is part of the oncology portfolio licensed to Pfizer for the US market and expected to be launched shortly," the statement said.
Fluorouracil is used to treat cancers of colon, rectum, head and neck.